Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Income from Continuing Operations (2016 - 2025)

Zevra Therapeutics' Income from Continuing Operations history spans 11 years, with the latest figure at 12165000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 134.04% year-over-year to 12165000.0; the TTM value through Dec 2025 reached 83229000.0, up 178.88%, while the annual FY2025 figure was 83229000.0, 178.88% up from the prior year.
  • Income from Continuing Operations reached 12165000.0 in Q4 2025 per ZVRA's latest filing, up from 544000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 74707000.0 in Q2 2025 to a low of 35739000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 5477750.0, with a median of 4857500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 622.12% in 2021, then plummeted 674.39% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 2703000.0 in 2021, then fell by 9.95% to 2972000.0 in 2022, then crashed by 569.31% to 19892000.0 in 2023, then plummeted by 79.67% to 35739000.0 in 2024, then surged by 134.04% to 12165000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Income from Continuing Operations are 12165000.0 (Q4 2025), 544000.0 (Q3 2025), and 74707000.0 (Q2 2025).